New combo therapy targets tough childhood leukemia
NCT ID NCT03591510
First seen Nov 01, 2025 · Last updated May 22, 2026 · Updated 28 times
Summary
This study tests a drug called midostaurin, given with standard chemotherapy, for children with a specific genetic type of acute myeloid leukemia (FLT3-mutated AML). The goal is to see if the combination is safe and helps control the disease. Twenty-two children will receive the drug twice daily during chemo and then continue it alone for 12 more cycles to keep the leukemia in check.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FLT3-MUTATED ACUTE MYELOID LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Novartis Investigative Site
Prague, 150 06, Czechia
-
Novartis Investigative Site
Berlin, 13353, Germany
-
Novartis Investigative Site
Essen, 45147, Germany
-
Novartis Investigative Site
Pavia, PV, 27100, Italy
-
Novartis Investigative Site
Roma, RM, 00165, Italy
-
Novartis Investigative Site
Torino, TO, 10126, Italy
-
Novartis Investigative Site
Naples, 80122, Italy
-
Novartis Investigative Site
Osaka, 5340021, Japan
-
Novartis Investigative Site
Amman, 11941, Jordan
-
Novartis Investigative Site
Krakow, 30-663, Poland
-
Novartis Investigative Site
Moscow, 117198, Russia
-
Novartis Investigative Site
Ljubljana, 1000, Slovenia
-
Novartis Investigative Site
Seoul, 03080, South Korea
-
Novartis Investigative Site
Seoul, 05505, South Korea
-
Novartis Investigative Site
Adana, Adana, 1330, Turkey (Türkiye)
Conditions
Explore the condition pages connected to this study.